

Supplementary Material

Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives

Yaling Tang ¹, Xinglian Xu ^{2,3}, Jiang Li ^{2,3}, Lulu Deng ^{2,3,*} and Shuzhen Mu ^{2,3,*}



¹ College of Pharmacy, Guizhou University, Guiyang 550025, China; gs.yltang@gzu.edu.cn

² State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; xinglian_xu2022@163.com (X.X.); jiangli@gzcnpcn (J.L.)



³ The Key Laboratory of Chemistry for Natural Products of Guizhou Province, Chinese Academy of Sciences, Guiyang 550014, China



* Correspondence: luludeng@gzcnpcn (L.D.); muzi0558@126.com (S.M.)

1. Table of contents.....	Page No.
2. ¹ H-NMR and ¹³ C-NMR spectra for compounds 1 and 2	2
3. ¹ H-NMR, ¹³ C-NMR, and HR-ESI-MS spectra for compounds 1a–1u and 2a–2l ..	4
4. The HPLC chromatograms of compounds 1 , 2 , 1a–1u , and 2a–2l	54
5. The preliminary screening results.....	66

^1H -NMR and ^{13}C -NMR spectra for compounds 1 and 2**Compound 1****Figure S1.** ^1H -NMR spectrum of 1 (600 MHz, CD_3OD).**Figure S2.** ^{13}C -NMR spectrum of 1 (150 MHz, CD_3OD).

Compound 2

Figure S3. ¹H-NMR spectrum of 2 (600 MHz, CD₃OD).Figure S4. ¹³C-NMR spectrum of 2 (150 MHz, CD₃OD).

^1H -NMR, ^{13}C -NMR, and HR-ESI-MS spectra for compounds 1a–1u and 2a–2l**Compound 1a****Figure S5.** ^1H -NMR spectrum of 1a (600 MHz, CDCl_3).**Figure S6.** ^{13}C -NMR spectrum of 1a (150 MHz, CDCl_3).

B-3 #83 RT: 0.37 AV: 1 NL: 1.54E7
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S7. HR-ESI-MS spectrum of **1a**.

Compound **1b**




Figure S8. 1H -NMR spectrum of **1b** (600 MHz, $CDCl_3$).




Figure S9. ¹³C-NMR spectrum of **1b** (150 MHz, CDCl₃).

B-4 #25 RT: 0.11 AV: 1 NL: 1.29E9
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S10. HR-ESI-MS spectrum of **1b**.

Compound 1c

Figure S11. ¹H-NMR spectrum of 1c (600 MHz, acetone-d₆).Figure S12. ¹³C-NMR spectrum of 1c (150 MHz, acetone-d₆).

B-10 #26 RT: 0.12 AV: 1 NL: 1.15E9
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S13. HR-ESI-MS spectrum of **1c**.

Compound **1d**




Figure S14. 1H -NMR spectrum of **1d** (600 MHz, $DMSO-d_6$).







Figure S16. HR-ESI-MS spectrum of **1d**.

Compound 1e

Figure S17. ¹H-NMR spectrum of 1e (600 MHz, CDCl₃).Figure S18. ¹³C-NMR spectrum of 1e (150 MHz, CDCl₃).

B-15 #26 RT: 0.11 AV: 1 NL: 5.05E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S19. HR-ESI-MS spectrum of **1e**.

Compound **1f**




Figure S20. 1H -NMR spectrum of **1f** (600 MHz, $CDCl_3$).




Figure S21. ^{13}C -NMR spectrum of **1f** (150 MHz, CDCl_3).

B-16 #33 RT: 0.14 AV: 1 NL: 2.21E6
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S22. HR-ESI-MS spectrum of **1f**.

Compound **1g**Figure S23. ¹H-NMR spectrum of **1g** (600 MHz, CDCl₃).Figure S24. ¹³C-NMR spectrum of **1g** (150 MHz, CDCl₃).

B-18 #25 RT: 0.11 AV: 1 NL: 3.28E9
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S25. HR-ESI-MS spectrum of **1g**.

Compound **1h**




Figure S26. 1H -NMR spectrum of **1h** (600 MHz, $CDCl_3$).




Figure S27. ¹³C-NMR spectrum of **1h** (150 MHz, CDCl₃).

B-20 #24 RT: 0.11 AV: 1 NL: 9.94E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S28. HR-ESI-MS spectrum of **1h**.

Compound **1i**Figure S29. ¹H-NMR spectrum of **1i** (600 MHz, CDCl₃).Figure S30. ¹³C-NMR spectrum of **1i** (150 MHz, CDCl₃).

B-22 #20 RT: 0.09 AV: 1 NL: 3.55E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S31. HR-ESI-MS spectrum of **1i**.

Compound **1j**




Figure S32. 1H -NMR spectrum of **1j** (600 MHz, $CDCl_3$).




Figure S33. ^{13}C -NMR spectrum of **1j** (150 MHz, CDCl_3).

B-23 #48 RT: 0.21 AV: 1 NL: 2.74E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S34. HR-ESI-MS spectrum of **1j**.

Compound 1k

Figure S35. ¹H-NMR spectrum of 1k (600 MHz, CDCl₃).Figure S36. ¹³C-NMR spectrum of 1k (150 MHz, CDCl₃).

B-24 #28 RT: 0.12 AV: 1 NL: 4.90E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S37. HR-ESI-MS spectrum of 1k.

Compound 1l




Figure S38. 1H -NMR spectrum of 1l (600 MHz, $CDCl_3$).




Figure S39. ^{13}C -NMR spectrum of **11** (150 MHz, CDCl_3).

B-21 #31 RT: 0.14 AV: 1 NL: 6.94E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]








Figure S40. HR-ESI-MS spectrum of **11**.

Compound **1m**Figure S41. ¹H-NMR spectrum of **1m** (600 MHz, CDCl₃).Figure S42. ¹³C-NMR spectrum of **1m** (150 MHz, CDCl₃).

Figure S43. HR-ESI-MS spectrum of **1m**.Compound **1n**Figure S44. ^1H -NMR spectrum of **1n** (600 MHz, CDCl_3).




Figure S45. ^{13}C -NMR spectrum of **1n** (150 MHz, CDCl_3).

B-6a #48 RT: 0.21 AV: 1 NL: 5.08E7
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S46. HR-ESI-MS spectrum of **1n**.

Compound **1o**Figure S47. ¹H-NMR spectrum of **1o** (600 MHz, CDCl₃).Figure S48. ¹³C-NMR spectrum of **1o** (150 MHz, CDCl₃).

B-6b #23 RT: 0.10 AV: 1 NL: 1.90E6
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S49. HR-ESI-MS spectrum of **1o**.

Compound **1p**




Figure S50. 1H -NMR spectrum of **1p** (600 MHz, $CDCl_3$).




Figure S51. ¹³C-NMR spectrum of **1p** (150 MHz, CDCl₃).

B-6c #23 RT: 0.10 AV: 1 NL: 1.07E6
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S52. HR-ESI-MS spectrum of **1p**.

Compound **1q**Figure S53. ¹H-NMR spectrum of **1q** (600 MHz, CDCl₃).Figure S54. ¹³C-NMR spectrum of **1q** (150 MHz, CDCl₃).

B-6d #19 RT: 0.08 AV: 1 NL: 5.31E7
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S55. HR-ESI-MS spectrum of **1q**.

Compound **1r**




Figure S56. 1H -NMR spectrum of **1r** (600 MHz, $CDCl_3$).




Figure S57. ^{13}C -NMR spectrum of **1r** (150 MHz, CDCl_3).






Figure S58. HR-ESI-MS spectrum of **1r**.

Compound 1s

Figure S59. ¹H-NMR spectrum of 1s (600 MHz, DMSO-d₆).Figure S60. ¹³C-NMR spectrum of 1s (150 MHz, DMSO-d₆).

B-9 #22 RT: 0.10 AV: 1 NL: 1.18E9
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S61. HR-ESI-MS spectrum of 1s.

Compound 1t




Figure S62. ¹H-NMR spectrum of 1t (600 MHz, CDCl₃).




Figure S63. ¹³C-NMR spectrum of **1t** (150 MHz, CDCl₃).

B-11 #25 RT: 0.11 AV: 1 NL: 3.22E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S64. HR-ESI-MS spectrum of **1t**.

B-14 #19 RT: 0.08 AV: 1 NL: 2.16E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S67. HR-ESI-MS spectrum of **1u**.

Compound **2a**




Figure S68. 1H -NMR spectrum of **2a** (600 MHz, $CDCl_3$).




Figure S69. ¹³C-NMR spectrum of 2a (150 MHz, CDCl₃).

S-3 #61 RT: 0.27 AV: 1 NL: 1.17E7
T: FTMS + p ESI Full ms [100.0000-1500.0000]





Figure S70. HR-ESI-MS spectrum of 2a.

Compound **2b****Figure S71.** ¹H-NMR spectrum of **2b** (600 MHz, CDCl₃).







Figure S73. HR-ESI-MS spectrum of **2b**.

Compound 2c

Figure S74. ¹H-NMR spectrum of 2c (600 MHz, CDCl₃).Figure S75. ¹³C-NMR spectrum of 2c (150 MHz, CDCl₃).

S-4 #22 RT: 0.10 AV: 1 NL: 2.24E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S76. HR-ESI-MS spectrum of 2c.

Compound 2d




Figure S77. ¹H-NMR spectrum of 2d (600 MHz, CDCl₃).




Figure S78. ^{13}C -NMR spectrum of 2d (150 MHz, CDCl_3).

S-5 #29 RT: 0.13 AV: 1 NL: 2.28E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S79. HR-ESI-MS spectrum of 2d.

Compound 2e

Figure S80. ¹H-NMR spectrum of 2e (600 MHz, CDCl₃).Figure S81. ¹³C-NMR spectrum of 2e (150 MHz, CDCl₃).

S-1 #28 RT: 0.12 AV: 1 NL: 2.29E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S82. HR-ESI-MS spectrum of 2e.

Compound 2f




Figure S83. ¹H-NMR spectrum of 2f (600 MHz, CDCl₃).




Figure S84. ¹³C-NMR spectrum of 2f (150 MHz, CDCl₃).

S-2 #34 RT: 0.15 AV: 1 NL: 4.27E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S85. HR-ESI-MS spectrum of 2f.

Compound **2g**Figure S86. ¹H-NMR spectrum of **2g** (600 MHz, CDCl₃).Figure S87. ¹³C-NMR spectrum of **2g** (150 MHz, CDCl₃).

S-11 #32 RT: 0.14 AV: 1 NL: 3.04E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S88. HR-ESI-MS spectrum of 2g

Compound 2h




Figure S89. ¹H-NMR spectrum of 2h (600 MHz, CDCl₃).




Figure S90. ¹³C-NMR spectrum of **2h** (150 MHz, CDCl₃).

S-12 #129 RT: 0.57 AV: 1 NL: 8.36E7
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S91. HR-ESI-MS spectrum of **2h**.

Compound 2i

Figure S92. ¹H-NMR spectrum of 2i (600 MHz, CDCl₃).Figure S93. ¹³C-NMR spectrum of 2i (150 MHz, CDCl₃).

S-7 #24 RT: 0.10 AV: 1 NL: 2.19E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S94. HR-ESI-MS spectrum of 2i.

Compound 2j




Figure S95. ¹H-NMR spectrum of 2j (600 MHz, CDCl₃).




Figure S96. ^{13}C -NMR spectrum of 2j (150 MHz, CDCl_3).

S-6 #30 RT: 0.13 AV: 1 NL: 2.01E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]






Figure S97. HR-ESI-MS spectrum of 2j.

Compound 2k

Figure S98. ¹H-NMR spectrum of 2k (600 MHz, CDCl₃).Figure S99. ¹³C-NMR spectrum of 2k (150 MHz, CDCl₃).

S-9 #31 RT: 0.14 AV: 1 NL: 1.16E9
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S100. HR-ESI-MS spectrum of 2k.

Compound 2l




Figure S101. 1H -NMR spectrum of 2l (600 MHz, $CDCl_3$).




Figure S102. ^{13}C -NMR spectrum of 2l (150 MHz, CDCl_3).

S-8 #27 RT: 0.12 AV: 1 NL: 5.70E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




Figure S103. HR-ESI-MS spectrum of 2l.

The HPLC chromatograms of compounds 1, 2, 1a–1u, and 2a–2l

HPLC chromatogram conditions

The chromatographic column was obtained from Thermo Science (Part No. 25905-254630), and the chromatograph was run with a flow rate of 1.0 mL/min and a column temperature maintained at 30 °C. The mobile phase system was acetonitrile (A) and 0.1% phosphoric acid aqueous solution (B); injection volume and detection wavelength are presented in Table 1.

Table S1. The mobile phase system, injection volume, and detection wavelength of compounds.

Compd.	A:B (%)	Injection Volume (μL)	Detection Wavelength (nm)
1, 2, 1a, 1c, 1e–1g, 1l, 1n, 1t, 2b, 2d, 2f–2h, 2j–2l	70:30	10.0	269
1b, 1d, 1h–1k, 1m, 1q–1r, 1u, 2a, 2c, 2e, 2i		0.8	269
1o, 1p	60:40	0.8	290
1s	90:10	0.8	285




Figure S104. HPLC chromatogram of 1.




Figure S105. HPLC chromatogram of 2.




Figure S106. HPLC chromatogram of 1a.




Figure S107. HPLC chromatogram of 1b.










Figure S108. HPLC chromatogram of 1c.

Figure S109. HPLC chromatogram of **1d**.Figure S110. HPLC chromatogram of **1e**.Figure S111. HPLC chromatogram of **1f**.

Figure S112. HPLC chromatogram of **1g**.Figure S113. HPLC chromatogram of **1h**.Figure S114. HPLC chromatogram of **1i**.




Figure S115. HPLC chromatogram of **1j**.




Figure S116. HPLC chromatogram of **1k**.




Figure S117. HPLC chromatogram of **1l**.




Figure S118. HPLC chromatogram of **1m**.




Figure S119. HPLC chromatogram of **1n**.







Figure S120. HPLC chromatogram of **1o**.

Figure S121. HPLC chromatogram of **1p**.Figure S122. HPLC chromatogram of **1q**.Figure S123. HPLC chromatogram of **1r**.




Figure S124. HPLC chromatogram of 1s.




Figure S125. HPLC chromatogram of 1t.







Figure S126. HPLC chromatogram of 1u.

Figure S127. HPLC chromatogram of **2a**.Figure S128. HPLC chromatogram of **2b**.Figure S129. HPLC chromatogram of **2c**.




Figure S130. HPLC chromatogram of **2d**.




Figure S131. HPLC chromatogram of **2e**.







Figure S132. HPLC chromatogram of **2f**.

Figure S133. HPLC chromatogram of **2g**.Figure S134. HPLC chromatogram of **2h**.Figure S135. HPLC chromatogram of **2i**.




Figure S136. HPLC chromatogram of 2j.




Figure S137. HPLC chromatogram of 2k.




Figure S138. HPLC chromatogram of 2l.

The preliminary screening results

Table S2. Preliminary screening test results.

Compd.	Concentration (μ M)	Cell Inhibition (%) \pm SD				
		HL-60	K-562	MV-4-11	Jurkat, Clone E6-1	THP-1
1	20	93.25% \pm 0.70%	21.44% \pm 1.30%	87.01% \pm 1.85%	96.77% \pm 0.85%	93.36% \pm 1.40%
1a	20	14.32% \pm 5.75%	3.12% \pm 2.16%	14.30% \pm 2.69%	−0.61% \pm 2.55%	7.53% \pm 1.68%
2	20	97.28% \pm 1.81%	90.59% \pm 1.36%	89.27% \pm 3.16%	97.79% \pm 0.72%	95.46% \pm 1.40%
2a	20	68.15% \pm 4.39%	17.96% \pm 5.52%	89.03% \pm 2.46%	97.82% \pm 0.70%	93.56% \pm 1.57%

Trop. J. Pharm. Res. **2015**, *14*, p1803.